No Data
Wanbangde Pharmaceutical Holding Group Co., Ltd.'s (SZSE:002082) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?
Wanbangde Pharmaceutical Holding Group (002082.SZ): The revenue from the South African industry accounts for approximately 25%.
On December 26, Gelonghui reported that Wanbangde Pharmaceutical Holding Group (002082.SZ) recently stated during an investor relations event that the company's South African operations mainly involve the agency and maintenance services for Medical Devices from Temic and orthopedic implant Medical Devices from Ailite, accounting for about 25% of income.
Wanbangde Pharmaceutical's HIE Drug Gets FDA Nod for Clinical Trial
It is expected to fill the gap in the Global neonatal HIE treatment field, as Wanbangde Pharmaceutical Holding Group's subsidiary WP103 clinical trial application has been accepted by the FDA.
① Currently, no Pharmaceutical product containing Huperzine A has been approved for the market in the USA, and there are no approved drugs globally for the treatment of neonatal HIE. ② Multiple preclinical studies have shown that Huperzine A has significant potential for treating neonatal HIE, with the hope of addressing the pathophysiological challenges of hypoxia-ischemia through a comprehensive mechanism of action.
Wanbangde Pharmaceutical Holding Group (002082.SZ): The clinical trial application for its subsidiary WP107 Pharmaceutical has been accepted by the FDA.
On December 15, Glonghui reported that Wanbangde Pharmaceutical Holding Group (002082.SZ) announced that its wholly-owned subsidiary Wanbangde Pharmaceutical Group Co., Ltd. received a written response from the USA Food and Drug Administration (referred to as "FDA") on December 15, 2024. The clinical trial application for WP107 (Huperzine A oral solution), independently developed by the company, for the treatment of "generalized myasthenia gravis" has officially been accepted. WP107 (Huperzine A oral solution) is a new oral formulation for the treatment of generalized myasthenia gravis developed by the company's innovative drug R&D team based on preclinical and clinical data.
Wanbangde (002082.SZ) has completed the establishment of its wholly-owned subsidiary, Zhejiang Wanbangde Industrial and Trade.
Wanbangde Pharmaceutical Holding Group (002082.SZ) announced that the company has decided to invest its own funds to establish a wholly-owned subsidiary, Zhejiang Wanbangde...
Wanbangde Pharmaceutical Holding Group Co., Ltd. (SZSE:002082) Not Doing Enough For Some Investors As Its Shares Slump 28%
